Parham Eshtehardi MD
@cardioobdoc.bsky.social
2.4K followers 1.2K following 1.4K posts
Preventive, Imaging, CardioOB Cardiologist & Scientist • Dad • Husband of a Stroke & Cancer Survivor Hero • Emory Trained • Atlanta, GA #CardioSky #CardioObstetrics #ACCRepOB 🔗 bit.ly/MyResearchPubs
Posts Media Videos Starter Packs
Pinned
cardioobdoc.bsky.social
#Skytorial for #CardioSky #MedSky newcomers
1/2

🦋 Follow #CardioSky community by using starter packs:
Cardio Journals & Societies
go.bsky.app/FfE1QRm
CardioSky I
go.bsky.app/562nfhZ
CardioSky II
go.bsky.app/R2XckyG

🦋 Add label "Cardiology" to your profile w/labeler
bsky.app/profile/meds...
Reposted by Parham Eshtehardi MD
yaelmaxwell.bsky.social
My first story from #EACTS2025 dives into a unique analysis comparing 5-year TAVI vs SAVR mortality that provoked some strong feelings about what type of research should inform guidelines. #CardioSky
www.tctmd.com/news/savr-be...
SAVR Bests TAVI for 5-Year Survival in Combined RCT, Observational Data
The findings sparked a debate about the merits of RCTs vs other study designs—one surgeon urged others to “read a textbook.”
www.tctmd.com
Reposted by Parham Eshtehardi MD
ajpcardio.bsky.social
🍽️ New paper: Beyond “low salt, low fat” — time to reimagine nutrition guidance in cardiac discharge summaries to better support recovery and long-term heart health.

📖 https://www.sciencedirect.com/science/article/pii/S2666667725003964

#CardioNutrition #HeartHealth #CardioSky #MedSky
Reposted by Parham Eshtehardi MD
scainews.bsky.social
🔬 New evidence suggests #DAPT after valve-in-valve #TAVR may reduce stroke risk compared to single therapy. However, the authors caution that more data is needed to make a decisive conclusion.

Learn more about the study ➡️ https://ow.ly/ySpY50X9gE6

#CardioSky
DAPT during valve-in-valve TAVR may reduce stroke risk—more data still required
New research suggests there may be a cardiovascular benefit to considering dual antiplatelet therapy for valve-in-valve TAVR patients.
ow.ly
Reposted by Parham Eshtehardi MD
cvinnovations.bsky.social
Deadline tomorrow! The #Peripheral Interventional Octagon "Extreme CLE and No-Option Patients" is coming up 10/23 @ 9 pm ET. Details at: https://cvinnovations.org/2025/09/08/intoct-extreme-cli/ #cardiology #CardioSky #MedSky
Reposted by Parham Eshtehardi MD
crfheart.bsky.social
Frontline professionals, it’s your time to lead.💥

The #TCT2025 Nurse and Technologist Symposium is where the future of cardiovascular care begins. Bold ideas. Real impact. Team-based innovation.

Register today! https://ow.ly/TEtU50X6FAZ

#CardioSky #MedSky
Reposted by Parham Eshtehardi MD
haoyin.bsky.social
A workflow to optimize siRNA targeting SMILR #LncRNA & #SmoothMuscleCell proliferation/migration ex vivo

30 min siRNA exposure is sufficient to penetrate ~10 lamellar layers of explanted saphenous vein media

Polyethylenimine as siRNA delivery agent

#JACCBTS 2025
www.jacc.org/doi/10.1016/...
Reposted by Parham Eshtehardi MD
scainews.bsky.social
⌛Deadline Approaching!⌛
Monday, Oct 13, is the last day to submit your #research to be featured in the upcoming #JSCAI special issue on health equity in #InterventionalCardiology.

Interested authors should contact [email protected]
Learn more about the issue➡️ https://ow.ly/amLq50X8HNT
Reposted by Parham Eshtehardi MD
ase360.bsky.social
🫀NEW PRODUCT🫀
Capture the insights and highlights from our #ASE2025 Scientific Sessions with this comprehensive online library!

These recordings include all keynote sessions, panel discussions, and special presentations. Shop now: bit.ly/42yCQqC
Reposted by Parham Eshtehardi MD
tctmd.bsky.social
The PCSK9 inhibitor evolocumab reduces the risk of MACE better than standard therapy alone in people with no previous history of CV events, based on data from the VESALIUS-CV trial. Read more here: www.tctmd.com/news/evolocu...
Evolocumab Wins for Primary Prevention in VESALIUS-CV
The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.
www.tctmd.com
Reposted by Parham Eshtehardi MD
ase360.bsky.social
Today is October 10 – take this as your sign to donate $10 to the #ASEFoundation!

If every ASE member gave just $10, we’d raise over $200,000 for charitable projects next year. asefoundation.org/
Reposted by Parham Eshtehardi MD
crfheart.bsky.social
✨ AI is changing everything, and healthcare is no exception. Join us for a visionary #TCT2025 keynote address as Dr. Robert Wachter shares bold insights from his new book “A Giant Leap.” Discover what AI means for the future of medicine & how you can navigate this new era! https://ow.ly/BCge50X9Yi5
Reposted by Parham Eshtehardi MD
accintouch.bsky.social
#AI-MRI body composition analysis has linked metrics such as visceral and muscle fat fraction to cardiometabolic risk, per a study of 33K adults. After further validation, it may become viable in identifying patients at high #cvMetabolic risk.

🔎 More: https://bit.ly/3WvCJIQ
Reposted by Parham Eshtehardi MD
ase360.bsky.social
UPCOMING WEBINAR: On November 20 from 5:30-6:30 PM ET, join us for the #ASEWebinar, "The Pulse on Politics: Congressional Appropriations Process and Federal Budget Updates!"

Sign up: bit.ly/4o8FEmE